CERS | Cerus Corp |
Surgical & Medical Instruments & Apparatus |
Book value per $ invested | $ 0.18 |
Leverage | 71.36% |
Market Cap | $ 308.2m |
PE | 0.00 |
Dividend Yield | 0.00% |
Profit | $ -19.7m |
Margin | -45.30% |
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.